LianBio (NASDAQ:LIAN – Get Free Report)’s share price dropped 1.5% during mid-day trading on Thursday . The company traded as low as $0.20 and last traded at $0.20. Approximately 101,190 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 1,037,083 shares. The stock had previously closed at $0.20.
LianBio Price Performance
The company’s 50-day moving average is $0.23 and its two-hundred day moving average is $0.28. The firm has a market cap of $21.61 million, a P/E ratio of -0.25 and a beta of 0.23.
LianBio Company Profile
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
Further Reading
- Five stocks we like better than LianBio
- How to Invest in Insurance Companies: A Guide
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- DuPont’s Electronics Spinoff: The Start of Something Big
- How to Invest in the Best Canadian Stocks
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.
